RN 517
Alternative Names: RN-517Latest Information Update: 18 Dec 2025
At a glance
- Originator Rona Therapeutics
- Class RNA
- Mechanism of Action RNA interference
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Metabolic disorders
Most Recent Events
- 18 Dec 2025 Preclinical trials in Metabolic disorders in China (Intrathecal), before December 2025 (Rona Therapeutics pipeline, December 2025)